SIGLEC1 and cancer: It is still unknown whether resident CD169+ lymph node macrophages in cancer patients are associated with a beneficial prognosis because of their function, or simply because of their mere presence in lymph nodes at an early tumor stage, thus being a prognostic biomarker.